San Diego, US - on January 10, 2020, DTX Pharma, a biomedical start-up based in San Diego, announced the completion of round A financing, totaling US $10.6 million. This round of financing is led by FBV fund 1, with the participation of Viva Biotech, Lilly pharmaceutical, Tech Coast Angels, Exsight ventures (NYC) and other investors with rich experience in the field of oligonucleotide therapy.
DTX Pharma will use this round of financing funds to accelerate the development and deployment of its proprietary platform to promote the research and development of RNA drugs. DTX Pharma can promote cell uptake and tissue selectivity by using fatty acids as carriers. This breakthrough makes it possible to target tissues other than the liver, thus creating more new therapeutic opportunities. The company is actively developing product pipelines for eye, central nervous system and various muscle diseases.